The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia
Open accessAbstract
Purpose: Cross-sectional studies show that cardiac abnormalities are common in long-term survivors of doxorubicin-treated childhood malignancies. Longitudinal data, however, are rare. Methods: Serial echocardiograms (N = 499) were obtained from 115 doxorubicin-treated long-term survivors of childhood acute lymphoblastic leukemia (median age at diagnosis, 4.8 years; median follow-up after completion of doxorubicin, 11.8 years). Results were expressed as z scores to indicate the number of standard deviations (SDs) above (+) or below (−) the normal predicted value. Median individual and cumulative doxorubicin doses were 30 mg/m 2 per dose and 352 mg/m 2, respectively. Results: Left ventricular fractional shortening was significantly reduced after doxorubicin therapy, and the reduction was related to cumulative dose. z scores for fractional shortening transiently improved before falling to −2.76 more than 12 years after diagnosis. Reduced fractional shortening was related to impaired contractility and increasing afterload, consequences of a progressive reduction of ventricular mass, and wall thickness relative to body-surface area. Left ventricular contractility fell significantly over time and was depressed at last follow-up in patients receiving more than 300 mg/m 2 of doxorubicin. Systolic and diastolic blood pressures were below normal more than 9 years after diagnosis. Even patients receiving lower cumulative doxorubicin doses experienced reduced mass and dimension. Fractional shortening and dimension at the end of therapy predicted these parameters 11.8 years later. Conclusion: Cardiac abnormalities were persistent and progressive after doxorubicin therapy. Inadequate ventricular mass with chronic afterload excess was associated with progressive contractile deficit and possibly reduced cardiac output and restrictive cardiomyopathy. The deficits were worst after highest cumulative doses of doxorubicin, but appeared even after low doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
US Department of Health and Human Services; National Cancer Institute (1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,947
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Self-citationLipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Self-citationMertens, A. C., Yasui, Y., Neglia, J. P., Potter, J. D., Nesbit, M. E., Ruccione, K., Smithson, W. A., & Robison, L. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3163 · Cited by 798
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Self-citationKrischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1544 · Cited by 476
Self-citationAnthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
Kremer, L. C. M., van Dalen, E. C., Offringa, M., Ottenkamp, J., & Voûte, P. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.191 · Cited by 399
Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2641 · Cited by 384
Self-citationEpidemiology of anthracycline cardiotoxicity in children and adults.
Ma, G., & Se, L. (1998) · PubMed · Cited by 341
Green, D. M., Grigoriev, Y. A., Nan, B., Takashima, J. R., Norkool, P. A., D’Angio, G. J., & Breslow, N. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.1926 · Cited by 319
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.
Zhou, S., Starkov, A. A., Froberg, M. K., Leino, R. L., & Wallace, K. B. (2001) · PubMed · Cited by 314
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C., Shaikh, S. L., Mone, S. M., Gelber, R. D., & Colan, S. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.102 · Cited by 308
Self-citationColan, S. D., Parness, I. A., Spevak, P. J., & Sanders, S. P. (1992) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)80282-7 · Cited by 285
Self-citationMöller, T. R., Garwicz, S., Barlow, L., Winther, J. F., Glattre, E., Olafsdottir, G., Olsen, J. H., Perfekt, R., Ritvanen, A., Sankila, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3173 · Cited by 259
Fas-Mediated Apoptosis in Adriamycin-Induced Cardiomyopathy in Rats: In Vivo Study
Nakamura, T., Ueda, Y., Juan, Y., Katsuda, S., Takahashi, H., & Koh, E. (2000) · Circulation · doi:10.1161/01.cir.102.5.572 · Cited by 223
Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study
Sorensen, K., Levitt, G. A., Bull, C., Dorup, I., & Sullivan, I. D. (2003) · Cancer · doi:10.1002/cncr.11274 · Cited by 214
Herman, E. H., Zhang, J., Lipshultz, S. E., Rifai, N., Chadwick, D., Takeda, K., Yu, Z.-X., & Ferrans, V. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2237 · Cited by 210
Self-citationDe Beer, E. L., Bottone, A. E., & Voest, E. E. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00765-8 · Cited by 185
Mitochondria as subcellular targets for clinically useful anthracyclines
Jung, K., & Reszka, R. C. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00128-4 · Cited by 182
Silverman, L., Declerck, L., Gelber, R., Dalton, V., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Moghrabi, A., Samson, Y., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401980 · Cited by 166
Self-citationGreen, D. M., Hyland, A. J., Chung, C. S., Zevon, M. A., & Hall, B. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3207 · Cited by 121
Herman, E. H., Zhang, J., Rifai, N., Lipshultz, S. E., Hasinoff, B. B., Chadwick, D. P., Knapton, A. D., Chai, J., & Ferrans, V. J. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100348 · Cited by 106
Self-citationParameter Estimation in Longitudinal Studies with Outcome-Dependent Follow-Up
Lipsitz, S. R., Fitzmaurice, G. M., Ibrahim, J. G., Gelber, R. D., & Lipshultz, S. E. (2002) · Biometrics · doi:10.1111/j.0006-341x.2002.00621.x · Cited by 99
Self-citationCardiovascular Trials in Long-Term Survivors of Childhood Cancer
Lipshultz, S. E., & Colan, S. D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.937 · Cited by 85
Self-citationLipshultz, S. E., Easley, K. A., Orav, E. J., Kaplan, S., Starc, T. J., Bricker, J. T., Lai, W. W., Moodie, D. S., Sopko, G. S., SCHLUCHTER, M. D., et al. (2001) · Circulation · doi:10.1161/01.cir.104.3.310 · Cited by 83
Self-citationVentricular dysfunction clinical research in infants, children and adolescents
Lipshultz, S. E. (2000) · Progress in Pediatric Cardiology · doi:10.1016/s1058-9813(00)00076-x · Cited by 79
Self-citationBorow, K. M., Colan, S. D., & Neumann, A. (1985) · Circulation · doi:10.1161/01.cir.72.3.515 · Cited by 75
Self-citationCardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines
Lipshultz, S. E., Vlach, S. A., Lipsitz, S. R., Sallan, S. E., Schwartz, M. L., & Colan, S. D. (2005) · PEDIATRICS · doi:10.1542/peds.2004-1004 · Cited by 73
Self-citationPoutanen, T., Tikanoja, T., Riikonen, P. V., Silvast, A., & Perkkiö, M. V. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.050 · Cited by 72
The mechanism for anthracycline-induced inhibition of collagen biosynthesis
Muszyńska, A., Wołczyński, S., & Palka, J. A. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00847-5 · Cited by 31
Cited by
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Anthracycline Chemotherapy and Cardiotoxicity
McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6711-0 · Cited by 956
Metadata
- Authors
- Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-04-20
- Volume
- 23
- Issue
- 12
- Pages
- 2629-2636
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161082810
- Cited by
- 727
- References
- 31
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.